STRO

Sutro is a clinical-stage oncology company whose value rests almost entirely on unproven pipeline science, not financials. The MD&A confirms the highest-priority wholly-owned asset, STRO-004 (tissue-factor ADC), only cleared its IND in October 2025 and began a Phase 1 dose-escalation trial in November 2025, with the first preliminary safety/PK readout not due until mid-2026. Everything else — STRO-006 and the STRO-227 dual-payload ADC — is still preclinical, with INDs targeted for 2026 and late-2026/early-2027. There is no approved product and no clear path to product revenue for years; the reported $102M FY2025 revenue is lumpy collaboration/royalty income (Astellas iADC deal, plus the Vaxcyte relationship whose PCV royalty was already sold to Blackstone), swinging from $154M (FY2023) to $62M (FY2024) to $102M (FY2025). A 4.9x P/S on that base is not a meaningful valuation anchor.

The balance sheet is the disqualifier. Stockholders' equity is negative at -$132M (down 397% YoY), total liabilities ($306M) exceed total assets ($174M), and cash & equivalents collapsed 69.5% to just $58.1M. Against operating cash burn of -$177M for FY2025, that cash alone is a fraction of a year of runway; even counting all $151M of current assets, the company is running against a hard funding wall. With only 16.6M shares outstanding after an ~80% share-count reduction (reverse split), a capital raise to fund the trials looks close to unavoidable, and dilution or restructured financing is the base case, not the tail.